Related Party - Gilead Sciences, Inc. - Additional Information (Details) $ / shares in Units, shares in Millions, $ in Millions	1 Months Ended	3 Months Ended		12 Months Ended
	Feb. 28, 2025 USD ($)	Mar. 31, 2025 USD ($) member $ / shares shares	Mar. 31, 2024 USD ($) shares	Dec. 31, 2023 USD ($) program	Dec. 31, 2021 USD ($) program	Dec. 31, 2020 USD ($)	Dec. 31, 2024 USD ($)
Related Party Transaction [Line Items]
Sale of stock, consideration received on transaction	$ 150.0
Number of programs, eligible to receive regulatory and commercial milestone payments | program				4
Revenue recognized from amounts in deferred revenue at the beginning of the period		$ 28.0	$ 142.0
Receivable from collaboration partners, current		15.0					$ 20.0
Gilead
Related Party Transaction [Line Items]
Sale of stock, consideration received on transaction		$ 15.0
Gilead
Related Party Transaction [Line Items]
Sale of stock, number of shares acquired in transaction (in shares) | shares		1.4
Related Party
Related Party Transaction [Line Items]
Percentage of outstanding common stock held		29.70%
Receivable from collaboration partners, current		$ 4.0					$ 6.0
Related Party | Research and Development
Related Party Transaction [Line Items]
Reimbursement from related party for shared costs		$ 5.0	$ 16.0
Purchase Agreement | Related Party
Related Party Transaction [Line Items]
Common stock shares issued (in shares) | shares			15.2
Funds received for stock purchase agreement			$ 320.0
Purchase price of common stock allocation to performance obligation			87.0
Percentage of premium purchase price of common stock		20.00%
Trailing days average closing price		5 days
Weighted average closing price of our common stock on grant date (in dollars per share) | $ / shares		$ 33.54
Number of board members | member		3
Purchase Agreement | Related Party | Maximum
Related Party Transaction [Line Items]
Right to purchase additional outstanding voting common stock percentage		35.00%
Gilead Collaboration Agreement
Related Party Transaction [Line Items]
Option payment upon completion of certain IND-enabling activities					$ 60.0
Option payment upon achievement of certain development milestones					150.0
Gilead Collaboration Agreement | Related Party
Related Party Transaction [Line Items]
Collaboration term for current and future clinical programs						10 years
Option continuation payment due upon eighth anniversary of agreement		$ 100.0
Option continuation payment due upon second anniversary of agreement		100.0
Option continuation payment due upon sixth anniversary of agreement		100.0
Option continuation payment due upon fourth anniversary of agreement		100.0
Upfront cash payment						$ 175.0
Option fee per program for all other programs entering clinical development to exercise option					$ 150.0
Number of research programs | program					2
Revenue recognized from amounts in deferred revenue at the beginning of the period		$ 28.0	$ 141.0
Gilead Collaboration Agreement | Related Party | Maximum
Related Party Transaction [Line Items]
Potential regulatory approval milestones payment receivable related to domvanalimab					$ 500.0
Amended Gilead Collaboration Agreement
Related Party Transaction [Line Items]
Number of exercise option to programs | program					3
Option payments received					$ 725.0
Removal of option continuation payment under agreement					$ 100.0
Option payment upon achievement of certain development milestones				$ 150.0
Number of programs, eligible to receive regulatory and commercial milestone payments | program				2
Amended Gilead Collaboration Agreement | Related Party
Related Party Transaction [Line Items]
Upfront cash payment				$ 17.5
Number of research programs | program				2
Option payment upon completion of certain IND-enabling activities				$ 45.0
Total upfront cash payment				35.0
Amended Gilead Collaboration Agreement | Related Party | Maximum
Related Party Transaction [Line Items]
Regulatory and commercial milestone payments received				$ 375.0